ArticleScientific reports2026
Ligand-based machine learning models to classify active compounds for prostaglandin EP2 receptor.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostaglandin receptors are pharmacologically validated targets with implications in several medical indications, including glaucoma, cardiac cyanotic disease, pulmonary hypertension, oncology, and various rare diseases. In this study, we developed a ligand-based machine learning (ML) model to classify chemical compounds as either active or inactive against the prostaglandin receptor EP2. From an initial set of 1,826 descriptors, 20 were selected to train random forest algorithms, yielding an area under the curve score (AUC) of > 0.8 for compound classification in the test set. Our resulting ML classifier showed an overall accuracy of 88.9% towards newly experimentally tested EP2 ligands. This adaptable and tractable workflow can be extended to other EP receptors and possibly other similar targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.